Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines total assets
Total assets on the balance sheet at the end of each period.
Revolution Medicines's total assets was $4.32B at Jun 30, 2026. For fiscal 2025 it was $2.35B, down 8.0% from the year before. The highest annual figure on record is $2.56B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.35B | -8.0% |
| FY2024 | Dec 31, 2024 | $2.56B | +24.1% |
| FY2023 | Dec 31, 2023 | $2.06B | +153.9% |
| FY2022 | Dec 31, 2022 | $811.93M | +10.0% |
| FY2021 | Dec 31, 2021 | $737.99M | +30.1% |
| FY2020 | Dec 31, 2020 | $567.40M | +157.3% |
| FY2019 | Dec 31, 2019 | $220.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.32B | +77.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.25B | -4.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.35B | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.25B | +27.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.43B | +34.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.37B | +23.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.56B | +24.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.76B | +79.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.81B | +68.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.91B | +77.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.06B | +153.9% |
| Q3 FY2023 | Sep 30, 2023 | $984.23M | +19.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.07B | +69.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.07B | +57.2% |
| Q4 FY2022 | Dec 31, 2022 | $811.93M | +10.0% |
| Q3 FY2022 | Sep 30, 2022 | $825.91M | +12.4% |
| Q2 FY2022 | Jun 30, 2022 | $632.80M | -18.2% |
| Q1 FY2022 | Mar 31, 2022 | $682.77M | -15.9% |
| Q4 FY2021 | Dec 31, 2021 | $737.99M | +30.1% |
| Q3 FY2021 | Sep 30, 2021 | $734.98M | +23.5% |
| Q2 FY2021 | Jun 30, 2021 | $774.05M | +70.5% |
| Q1 FY2021 | Mar 31, 2021 | $811.65M | +78.6% |
| Q4 FY2020 | Dec 31, 2020 | $567.40M | +157.3% |
| Q3 FY2020 | Sep 30, 2020 | $595.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $453.96M | – |
| Q1 FY2020 | Mar 31, 2020 | $454.34M | – |
| Q4 FY2019 | Dec 31, 2019 | $220.53M | – |